tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GPCR Stock Latest News

These 3 Stocks Could Explode Higher, Say Five-Star Analysts – 11/28/2025
Market NewsThese 3 Stocks Could Explode Higher, Say Five-Star Analysts – 11/28/2025
7d ago
GPCR
TBPH
Promising Potential of Structure Therapeutics’ Aleniglipron in the Incretin-Based Therapy Landscape
PremiumRatings
Promising Potential of Structure Therapeutics’ Aleniglipron in the Incretin-Based Therapy Landscape
10d ago
GPCR
Buy Rating for Structure Therapeutics, Inc.: Potential Disruption in Obesity Treatment with Amylin Agonists
PremiumRatings
Buy Rating for Structure Therapeutics, Inc.: Potential Disruption in Obesity Treatment with Amylin Agonists
12d ago
GPCR
Buy Rating on Structure Therapeutics, Inc. Driven by Aleniglipron’s Potential in the Obesity Market
PremiumRatings
Buy Rating on Structure Therapeutics, Inc. Driven by Aleniglipron’s Potential in the Obesity Market
16d ago
GPCR
Structure Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Structure Therapeutics Reports Q3 2025 Financial Results
25d ago
GPCR
Buy Rating for Structure Therapeutics: Potential Breakthrough in Obesity Treatment with Aleniglipron
PremiumRatingsBuy Rating for Structure Therapeutics: Potential Breakthrough in Obesity Treatment with Aleniglipron
26d ago
GPCR
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Q3 Earnings Cheat Sheet
Premium
Pre-Earnings
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Q3 Earnings Cheat Sheet
26d ago
GPCR
Positive Buy Rating for Structure Therapeutics Driven by Promising Product Outlook and Strong Financial Position
Premium
Ratings
Positive Buy Rating for Structure Therapeutics Driven by Promising Product Outlook and Strong Financial Position
29d ago
GPCR
Promising Market Potential for Structure Therapeutics’ Aleniglipron Driven by Positive Clinical Trials and Strategic Advantages
PremiumRatings
Promising Market Potential for Structure Therapeutics’ Aleniglipron Driven by Positive Clinical Trials and Strategic Advantages
1M ago
GPCR
Citi adds ‘positive 90-day catalyst watch’ on Structure Therapeutics
PremiumThe Fly
Citi adds ‘positive 90-day catalyst watch’ on Structure Therapeutics
1M ago
GPCR
Strong Market Demand and Convenience Drive Buy Rating for Structure Therapeutics
PremiumRatings
Strong Market Demand and Convenience Drive Buy Rating for Structure Therapeutics
1M ago
GPCR
Buy Rating for Structure Therapeutics: Aleniglipron’s Market Potential and Acquisition Appeal
PremiumRatings
Buy Rating for Structure Therapeutics: Aleniglipron’s Market Potential and Acquisition Appeal
2M ago
GPCR
Promising Market Potential for Structure Therapeutics: Buy Rating Backed by Superior Trial Results and Market Opportunities
PremiumRatingsPromising Market Potential for Structure Therapeutics: Buy Rating Backed by Superior Trial Results and Market Opportunities
3M ago
GPCR
Optimistic Buy Rating for Structure Therapeutics Driven by Aleniglipron’s Potential in Obesity and T2D Markets
Premium
Ratings
Optimistic Buy Rating for Structure Therapeutics Driven by Aleniglipron’s Potential in Obesity and T2D Markets
3M ago
GPCR
Structure Therapeutics price target lowered to $90 from $92 at Guggenheim
Premium
The Fly
Structure Therapeutics price target lowered to $90 from $92 at Guggenheim
4M ago
GPCR
Structure Therapeutics price target raised to $75 from $60 at H.C. Wainwright
PremiumThe Fly
Structure Therapeutics price target raised to $75 from $60 at H.C. Wainwright
4M ago
LLY
GPCR
Structure Therapeutics price target lowered to $44 from $60 at Leerink
PremiumThe Fly
Structure Therapeutics price target lowered to $44 from $60 at Leerink
4M ago
GPCR
Structure Therapeutics price target lowered to $87 from $89 at Citizens JMP
PremiumThe Fly
Structure Therapeutics price target lowered to $87 from $89 at Citizens JMP
4M ago
GPCR
Structure Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Structure Therapeutics Reports Q2 2025 Financial Results
4M ago
GPCR
Promising Developments in Structure Therapeutics’ Clinical Trials Drive Buy Rating
PremiumRatingsPromising Developments in Structure Therapeutics’ Clinical Trials Drive Buy Rating
4M ago
GPCR
Structure Therapeutics files automatic mixed securities shelf
Premium
The Fly
Structure Therapeutics files automatic mixed securities shelf
4M ago
GPCR
Structure Therapeutics initiated with a Buy at Clear Street
Premium
The Fly
Structure Therapeutics initiated with a Buy at Clear Street
4M ago
GPCR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >